Alexander L Rakhmilevich Selected Research

lorukafusp alfa

1/2021	Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma.
1/2019	Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.
8/2013	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
11/2011	Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.
4/2011	Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
7/2004	Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
1/2004	NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander L Rakhmilevich Research Topics

Disease

38	Neoplasms (Cancer) 09/2022 - 09/2002
10	Neuroblastoma 01/2022 - 01/2004
6	Melanoma (Melanoma, Malignant) 01/2022 - 01/2011
6	Experimental Melanoma 01/2021 - 05/2005
4	Necrosis 05/2011 - 06/2006
3	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2004
2	Lymphoma (Lymphomas) 01/2021 - 02/2009
2	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2004
2	Adenocarcinoma 08/2004 - 09/2002
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Colonic Neoplasms (Colon Cancer) 08/2009
1	Sarcoma (Soft Tissue Sarcoma) 08/2008
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2007
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 06/2006
1	Splenomegaly 09/2002
1	Lymphadenopathy 09/2002
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2002

Drug/Important Bio-Agent (IBA)

11	Interleukin-2 (IL2)IBA 01/2022 - 01/2004
8	Monoclonal AntibodiesIBA 10/2020 - 08/2004
7	lorukafusp alfaIBA 01/2021 - 01/2004
6	CytokinesIBA 01/2021 - 06/2006
5	Interleukin-12 (IL 12)IBA 09/2022 - 09/2002
4	OligodeoxyribonucleotidesIBA 01/2021 - 03/2007
3	VaccinesIBA 09/2022 - 01/2021
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2012 - 06/2006
3	DNA (Deoxyribonucleic Acid)IBA 11/2011 - 09/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2007 - 01/2006
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	AntibodiesIBA 10/2020 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2018
2	AntigensIBA 04/2013 - 01/2011
2	Interferon-gamma (Interferon, gamma)IBA 10/2012 - 01/2004
2	LipopolysaccharidesIBA 10/2012 - 06/2006
2	ResveratrolIBA 11/2011 - 05/2011
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2011 - 12/2008
1	carboxyaminoimidazole ribotide (CAIR)IBA 01/2022
1	Radioisotopes (Radionuclides)IBA 01/2021
1	bempegaldesleukinIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 10/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Neoplasm AntibodiesIBA 01/2020
1	Therapeutic UsesIBA 01/2018
1	ChemokinesIBA 08/2015
1	Gemcitabine FDA Link 12/2013
1	Fluorouracil (Carac)FDA LinkGeneric 12/2013
1	Recombinant ProteinsIBA 08/2013
1	EpitopesIBA 01/2011
1	tucotuzumab celmoleukinIBA 08/2009
1	Interleukin-1alpha (Interleukin 1 alpha)IBA 03/2007
1	TNF-Related Apoptosis-Inducing LigandIBA 03/2007
1	Fas Ligand Protein (Fas Ligand)IBA 03/2007
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2004
1	Histocompatibility Antigens Class IIBA 01/2004
1	Complementary DNA (cDNA)IBA 09/2002
1	LipidsIBA 09/2002

Therapy/Procedure

18	Immunotherapy 09/2022 - 09/2002
9	Therapeutics 01/2021 - 01/2004
6	Radiotherapy 01/2022 - 01/2016
5	Ligation 08/2012 - 05/2005
4	Drug Therapy (Chemotherapy) 12/2013 - 06/2009
2	Intraperitoneal Injections 01/2013 - 05/2005
1	Neoadjuvant Therapy 01/2022
1	Intravenous Injections 10/2020
1	Radiofrequency Ablation 08/2009
1	Aftercare (After-Treatment) 08/2009
1	Transplantation 06/2009